← Back to headlines
HUTCHMED Secures Regulatory Approval for Fanregratinib to Treat Rare Liver Cancer
Chinese biotech firm HUTCHMED announced that China's National Medical Products Administration has approved its drug ATLED (fanregratinib) for patients with FGFR2-fusion/rearrangement intrahepatic cholangiocarcinoma.
28 Aug, 00:00 — 28 Aug, 00:00
